Primary Progressive Multiple Sclerosis:
"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition....
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Milano
Springer Milan
2002
|
| Schriftenreihe: | Topics in Neuroscience
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | "Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic |
| Beschreibung: | 1 Online-Ressource (X, 128 p. 5 illus) |
| ISBN: | 9788847022348 |
| DOI: | 10.1007/978-88-470-2234-8 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046146644 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2002 |||| o||u| ||||||eng d | ||
| 020 | |a 9788847022348 |9 978-88-470-2234-8 | ||
| 024 | 7 | |a 10.1007/978-88-470-2234-8 |2 doi | |
| 035 | |a (ZDB-2-SME)978-88-470-2234-8 | ||
| 035 | |a (OCoLC)1119078223 | ||
| 035 | |a (DE-599)BVBBV046146644 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.8 |2 23 | |
| 084 | |a YG 6003 |0 (DE-625)153507:12909 |2 rvk | ||
| 245 | 1 | 0 | |a Primary Progressive Multiple Sclerosis |c edited by Massimo Filippi, Giancarlo Comi |
| 264 | 1 | |a Milano |b Springer Milan |c 2002 | |
| 300 | |a 1 Online-Ressource (X, 128 p. 5 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Topics in Neuroscience | |
| 520 | |a "Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic | ||
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Neuroradiology | |
| 650 | 4 | |a Neurology | |
| 650 | 4 | |a Radiology, Medical | |
| 650 | 0 | 7 | |a Multiple Sklerose |0 (DE-588)4040693-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Multiple Sklerose |0 (DE-588)4040693-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Filippi, Massimo |4 edt | |
| 700 | 1 | |a Comi, Giancarlo |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847022362 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847001671 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847022355 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-88-470-2234-8 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031526829 | ||
| 966 | e | |u https://doi.org/10.1007/978-88-470-2234-8 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180484887937024 |
|---|---|
| any_adam_object | |
| author2 | Filippi, Massimo Comi, Giancarlo |
| author2_role | edt edt |
| author2_variant | m f mf g c gc |
| author_facet | Filippi, Massimo Comi, Giancarlo |
| building | Verbundindex |
| bvnumber | BV046146644 |
| classification_rvk | YG 6003 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-88-470-2234-8 (OCoLC)1119078223 (DE-599)BVBBV046146644 |
| dewey-full | 616.8 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.8 |
| dewey-search | 616.8 |
| dewey-sort | 3616.8 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-88-470-2234-8 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03314nmm a2200517zc 4500</leader><controlfield tag="001">BV046146644</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2002 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9788847022348</subfield><subfield code="9">978-88-470-2234-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-88-470-2234-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-88-470-2234-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119078223</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146644</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.8</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 6003</subfield><subfield code="0">(DE-625)153507:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Primary Progressive Multiple Sclerosis</subfield><subfield code="c">edited by Massimo Filippi, Giancarlo Comi</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Milano</subfield><subfield code="b">Springer Milan</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 128 p. 5 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Topics in Neuroscience</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroradiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology, Medical</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Multiple Sklerose</subfield><subfield code="0">(DE-588)4040693-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Multiple Sklerose</subfield><subfield code="0">(DE-588)4040693-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Filippi, Massimo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Comi, Giancarlo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847022362</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847001671</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847022355</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-88-470-2234-8</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526829</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-88-470-2234-8</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046146644 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:30Z |
| institution | BVB |
| isbn | 9788847022348 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526829 |
| oclc_num | 1119078223 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 128 p. 5 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| publisher | Springer Milan |
| record_format | marc |
| series2 | Topics in Neuroscience |
| spelling | Primary Progressive Multiple Sclerosis edited by Massimo Filippi, Giancarlo Comi Milano Springer Milan 2002 1 Online-Ressource (X, 128 p. 5 illus) txt rdacontent c rdamedia cr rdacarrier Topics in Neuroscience "Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic Neurology Neuroradiology Radiology, Medical Multiple Sklerose (DE-588)4040693-3 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Multiple Sklerose (DE-588)4040693-3 s DE-604 Filippi, Massimo edt Comi, Giancarlo edt Erscheint auch als Druck-Ausgabe 9788847022362 Erscheint auch als Druck-Ausgabe 9788847001671 Erscheint auch als Druck-Ausgabe 9788847022355 https://doi.org/10.1007/978-88-470-2234-8 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Primary Progressive Multiple Sclerosis Neurology Neuroradiology Radiology, Medical Multiple Sklerose (DE-588)4040693-3 gnd |
| subject_GND | (DE-588)4040693-3 (DE-588)4143413-4 |
| title | Primary Progressive Multiple Sclerosis |
| title_auth | Primary Progressive Multiple Sclerosis |
| title_exact_search | Primary Progressive Multiple Sclerosis |
| title_full | Primary Progressive Multiple Sclerosis edited by Massimo Filippi, Giancarlo Comi |
| title_fullStr | Primary Progressive Multiple Sclerosis edited by Massimo Filippi, Giancarlo Comi |
| title_full_unstemmed | Primary Progressive Multiple Sclerosis edited by Massimo Filippi, Giancarlo Comi |
| title_short | Primary Progressive Multiple Sclerosis |
| title_sort | primary progressive multiple sclerosis |
| topic | Neurology Neuroradiology Radiology, Medical Multiple Sklerose (DE-588)4040693-3 gnd |
| topic_facet | Neurology Neuroradiology Radiology, Medical Multiple Sklerose Aufsatzsammlung |
| url | https://doi.org/10.1007/978-88-470-2234-8 |
| work_keys_str_mv | AT filippimassimo primaryprogressivemultiplesclerosis AT comigiancarlo primaryprogressivemultiplesclerosis |